Results of Phase 2 clinical trial with KH176 in adult mitochondrial disease patients will be presented at Dutch Life Sciences conference.
NIJMEGEN, The Netherlands – Khondrion, a clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today that its CEO Prof. dr. Jan Smeitink will present first results of Khondrion’s KHENERGY study at the Dutch Life Sciences Conference in Oss, The Netherlands, on November 22 at 10 am.
The KHENERGY study is a single-center, double-blinded, randomized, placebo-controlled, explorative 2-way cross over Phase 2 trial involving 20 patients with MELAS syndrome, MIDD syndrome or mixed phenotypes harboring the m.3243A>G mutation in the mitochondrial genome. The study was supervised by dr. Mirian Janssen (MD, PhD), of the Radboud Center for Mitochondrial Medicine at the Radboudumc, Nijmegen, The Netherlands.